{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:53:48Z","timestamp":1795017228513,"version":"4.10.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer (OC) is often characterized by poor prognosis due to paclitaxel (TAX) resistance, with ferredoxin 1 (FDX1) emerging as a key mediator of copper metabolism. The present study aimed to elucidate the role of FDX1 in TAX resistance and to evaluate the efficacy of pH\/reactive oxygen species (ROS)-responsive nanomicelles (PPD\/PDP@si-FDX1) in reversing this resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TAX-resistant A2780 and SKOV3 cells were established by gradient exposure, and FDX1 expression was assessed using Western blotting. FDX1 was either overexpressed or silenced, and resistance was evaluated using CCK-8, clonogenic, scratch, and Transwell assays. Autophagic activity was examined through Western blotting, immunofluorescence, and transmission electron microscopy. Mechanistic validation involved the ULK1 activator BL-918 and the copper chelator TTM. PPD\/PDP@si-FDX1 nanomicelles were prepared via self-assembly, with structural and responsive characteristics analyzed by transmission electron microscopy (TEM), dynamic light scattering (DLS), and drug release profiling. Tumor penetration and in vivo antitumor efficacy were examined using multicellular spheroids and subcutaneous xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FDX1 overexpression elevated intracellular copper, activated the ULK1\/ATG13 autophagic axis, and enhanced TAX resistance; silencing FDX1 reversed these effects. Copper chelators or ULK1 inhibition phenocopied FDX1 silencing. PPD\/PDP@si-FDX1 demonstrated pH\/ROS-responsive tumor accumulation and enhanced si-FDX1 delivery. In vivo, it significantly suppressed tumor growth and restored TAX sensitivity, outperforming free si-FDX1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FDX1 drives TAX resistance via copper-dependent ULK1\/ATG13 activation; PPD\/PDP@si-FDX1 nanomicelles effectively reverse resistance, offering a promising strategy for OC therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                    <jats:p>Graphic abstract. The molecular mechanism of PPD\/PDP@si-FDX1 exhibits antitumor effects<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03589-z","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:26:05Z","timestamp":1776925565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ferrodoxin 1 (FDX1) drives paclitaxel resistance in ovarian cancer via copper metabolism and ULK1\/ATG13-mediated autophagy: overcome by pH\/ROS-responsive PPD\/PDP@si-FDX1 nanomicelles"],"prefix":"10.1186","volume":"45","author":[{"given":"Yangmei","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"3589_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21:389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"key":"3589_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35:151\u20136.","journal-title":"Semin Oncol Nurs"},{"key":"3589_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jconrel.2019.08.034","volume":"311\u2013312","author":"AM Khalifa","year":"2019","unstructured":"Khalifa AM, Elsheikh MA, Khalifa AM, Elnaggar YSR. Current strategies for different paclitaxel-loaded Nano-delivery systems towards therapeutic applications for ovarian carcinoma: A review Article. J Controlled Release. 2019;311\u2013312:125\u201337.","journal-title":"J Controlled Release"},{"key":"3589_CR4","first-page":"426","volume":"16","author":"UA Matulonis","year":"2018","unstructured":"Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol. 2018;16:426\u201337.","journal-title":"Clin Adv Hematol Oncol"},{"key":"3589_CR5","first-page":"418","volume":"32","author":"LR Boyd","year":"2018","unstructured":"Boyd LR, Muggia FM. Carboplatin\/Paclitaxel induction in ovarian cancer: the finer points. Oncol (Williston Park). 2018;32:418\u201320.","journal-title":"Oncol (Williston Park)"},{"key":"3589_CR6","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1002\/jcp.26289","volume":"233","author":"L Norouzi-Barough","year":"2018","unstructured":"Norouzi-Barough L, Sarookhani MR, Sharifi M, Moghbelinejad S, Jangjoo S, Salehi R. Molecular mechanisms of drug resistance in ovarian cancer. J Cell Physiol. 2018;233:4546\u201362.","journal-title":"J Cell Physiol"},{"key":"3589_CR7","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1002\/cam4.2560","volume":"8","author":"A Chandra","year":"2019","unstructured":"Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8:7018\u201331.","journal-title":"Cancer Med"},{"key":"3589_CR8","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2021.147","author":"M Ortiz","year":"2022","unstructured":"Ortiz M, Wabel E, Mitchell K, Horibata S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 2022. https:\/\/doi.org\/10.20517\/cdr.2021.147.","journal-title":"Cancer Drug Resist"},{"key":"3589_CR9","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022;232:114205.","journal-title":"Eur J Med Chem"},{"key":"3589_CR10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1089\/cbr.2019.3390","volume":"37","author":"Z Yu","year":"2022","unstructured":"Yu Z, Wang Y, Wang B, Zhai J. Metformin affects Paclitaxel sensitivity of ovarian cancer cells through autophagy mediated by long noncoding RNASNHG7\/miR-3127-5p axis. Cancer Biotherapy Radiopharmaceuticals. 2022;37:792\u2013801.","journal-title":"Cancer Biotherapy Radiopharmaceuticals"},{"key":"3589_CR11","doi-asserted-by":"publisher","first-page":"114458","DOI":"10.1016\/j.biopha.2023.114458","volume":"161","author":"J \u0160kubn\u00edk","year":"2023","unstructured":"\u0160kubn\u00edk J, Svobodov\u00e1 Pavl\u00ed\u010dkov\u00e1 V, Ruml T, Rimpelov\u00e1 S. Autophagy in cancer resistance to paclitaxel: development of combination strategies. Biomed Pharmacother. 2023;161:114458.","journal-title":"Biomed Pharmacother"},{"key":"3589_CR12","doi-asserted-by":"publisher","unstructured":"Zhao Y, Wang W, Pan W, Yu Y, Huang W, Gao J, et al. WWOX promotes apoptosis and inhibits autophagy in paclitaxel\u2013treated ovarian carcinoma cells. Mol Med Rep. 2020;23. https:\/\/doi.org\/10.3892\/mmr.2020.11754.","DOI":"10.3892\/mmr.2020.11754"},{"key":"3589_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2147\/OTT.S240434","volume":"13","author":"L Gu","year":"2020","unstructured":"Gu L, Li Q, Liu H, Lu X, Zhu M. Long noncoding RNA TUG1 promotes Autophagy-Associated Paclitaxel resistance by sponging miR-29b-3p in ovarian cancer cells. OTT. 2020;13:2007\u201319.","journal-title":"OTT"},{"key":"3589_CR14","doi-asserted-by":"publisher","first-page":"112578","DOI":"10.1016\/j.jinorgbio.2024.112578","volume":"257","author":"B Chen","year":"2024","unstructured":"Chen B, Liu J. Mechanisms associated with Cuproptosis and implications for ovarian cancer. J Inorg Biochem. 2024;257:112578.","journal-title":"J Inorg Biochem"},{"key":"3589_CR15","doi-asserted-by":"publisher","first-page":"116247","DOI":"10.1016\/j.biopha.2024.116247","volume":"172","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Zeng W, Chen Y, Zhu X. The effect of lipid metabolism on cuproptosis-inducing cancer therapy. Biomed Pharmacother. 2024;172:116247.","journal-title":"Biomed Pharmacother"},{"key":"3589_CR16","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1080\/15548627.2023.2200554","volume":"19","author":"Q Xue","year":"2023","unstructured":"Xue Q, Kang R, Klionsky DJ, Tang D, Liu J, Chen X. Copper metabolism in cell death and autophagy. Autophagy. 2023;19:2175\u201395.","journal-title":"Autophagy"},{"key":"3589_CR17","doi-asserted-by":"publisher","unstructured":"Zhang C, Huang T, Li L. Targeting Cuproptosis for cancer therapy: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17. https:\/\/doi.org\/10.1186\/s13045-024-01589-8.","DOI":"10.1186\/s13045-024-01589-8"},{"key":"3589_CR18","doi-asserted-by":"publisher","unstructured":"Li L, Zhou H, Zhang C. Cuproptosis in cancer: biological implications and therapeutic opportunities. Cell Mol Biol Lett. 2024;29. https:\/\/doi.org\/10.1186\/s11658-024-00608-3.","DOI":"10.1186\/s11658-024-00608-3"},{"key":"3589_CR19","doi-asserted-by":"publisher","unstructured":"Update on Nanotechnology-based Drug Delivery. Systems in cancer treatment. AR. 2017;37. https:\/\/doi.org\/10.21873\/anticanres.12044.","DOI":"10.21873\/anticanres.12044"},{"key":"3589_CR20","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1016\/j.nano.2018.06.015","volume":"14","author":"J Leong","year":"2018","unstructured":"Leong J, Chin W, Ke X, Gao S, Kong H, Hedrick JL, et al. Disease-directed design of biodegradable polymers: reactive oxygen species and pH-responsive micellar nanoparticles for anticancer drug delivery. Nanomed Nanotechnol Biol Med. 2018;14:2666\u201377.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"3589_CR21","doi-asserted-by":"publisher","first-page":"111067","DOI":"10.1016\/j.colsurfb.2020.111067","volume":"193","author":"M Su","year":"2020","unstructured":"Su M, Xiao S, Shu M, Lu Y, Zeng Q, Xie J, et al. Enzymatic multifunctional biodegradable polymers for pH- and ROS-responsive anticancer drug delivery. Colloids Surf B. 2020;193:111067.","journal-title":"Colloids Surf B"},{"key":"3589_CR22","doi-asserted-by":"publisher","unstructured":"Dai L, Li X, Duan X, Li M, Niu P, Xu H, et al. A pH\/ROS Cascade-Responsive Charge\u2010Reversal nanosystem with Self\u2010Amplified drug release for synergistic Oxidation\u2010Chemotherapy. Adv Sci. 2018;6. https:\/\/doi.org\/10.1002\/advs.201801807.","DOI":"10.1002\/advs.201801807"},{"key":"3589_CR23","doi-asserted-by":"publisher","unstructured":"Zhang X, Zhu T, Miao Y, Zhou L, Zhang W. Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy. J Nanobiotechnol. 2020;18. https:\/\/doi.org\/10.1186\/s12951-020-00691-6.","DOI":"10.1186\/s12951-020-00691-6"},{"key":"3589_CR24","doi-asserted-by":"publisher","unstructured":"Wang H, Shi W, Zeng D, Huang Q, Xie J, Wen H, et al. pH-activated, mitochondria-targeted, and redox-responsive delivery of Paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer. J Nanobiotechnol. 2021;19. https:\/\/doi.org\/10.1186\/s12951-021-00895-4.","DOI":"10.1186\/s12951-021-00895-4"},{"key":"3589_CR25","doi-asserted-by":"publisher","unstructured":"Su Y, Liu B, Wang B, Chan L, Xiong C, Lu L, et al. Progress and challenges in tumor ferroptosis treatment strategies: A comprehensive review of metal complexes and nanomedicine. Small. 2024;20. https:\/\/doi.org\/10.1002\/smll.202310342.","DOI":"10.1002\/smll.202310342"},{"key":"3589_CR26","doi-asserted-by":"crossref","unstructured":"LEE C. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells. Mol Med Rep. 2012; 12: 1485\u201392.","DOI":"10.3892\/mmr.2015.3542"},{"key":"3589_CR27","doi-asserted-by":"publisher","first-page":"121010","DOI":"10.1016\/j.biomaterials.2021.121010","volume":"276","author":"L Dai","year":"2021","unstructured":"Dai L, Li X, Zheng X, Fu Z, Yao M, Meng S, et al. TGF-\u03b2 blockade-improved chemo-immunotherapy with pH\/ROS cascade-responsive micelle via tumor microenvironment remodeling. Biomaterials. 2021;276:121010.","journal-title":"Biomaterials"},{"key":"3589_CR28","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254\u201361.","journal-title":"Science"},{"key":"3589_CR29","doi-asserted-by":"publisher","unstructured":"Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023;22. https:\/\/doi.org\/10.1186\/s12943-023-01732-y.","DOI":"10.1186\/s12943-023-01732-y"},{"key":"3589_CR30","doi-asserted-by":"publisher","unstructured":"Zulkifli M, Spelbring AN, Zhang Y, Soma S, Chen S, Li L et al. FDX1-dependent and independent mechanisms of elesclomol-mediated intracellular copper delivery. Proc. Natl. Acad. Sci. U.S.A. 2023; 120. https:\/\/doi.org\/10.1073\/pnas.2216722120","DOI":"10.1073\/pnas.2216722120"},{"key":"3589_CR31","doi-asserted-by":"publisher","first-page":"103302","DOI":"10.1016\/j.redox.2024.103302","volume":"75","author":"B Sun","year":"2024","unstructured":"Sun B, Ding P, Song Y, Zhou J, Chen X, Peng C, et al. FDX1 downregulation activates mitophagy and the PI3K\/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production. Redox Biol. 2024;75:103302.","journal-title":"Redox Biol"},{"key":"3589_CR32","doi-asserted-by":"publisher","unstructured":"Fan G, Qin J, Fu X, Si X, Li L, Yang K, et al. Low-Intensity focused ultrasound targeted microbubble destruction enhanced Paclitaxel sensitivity by decreasing autophagy in Paclitaxel-Resistant ovarian cancer. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.823956.","DOI":"10.3389\/fonc.2022.823956"},{"key":"3589_CR33","doi-asserted-by":"publisher","first-page":"127436","DOI":"10.1016\/j.jtemb.2024.127436","volume":"84","author":"Y Lin","year":"2024","unstructured":"Lin Y, Yuan M, Wang G. Copper homeostasis and Cuproptosis in gynecological disorders: pathogenic insights and therapeutic implications. J Trace Elem Med Biol. 2024;84:127436.","journal-title":"J Trace Elem Med Biol"},{"key":"3589_CR34","doi-asserted-by":"publisher","first-page":"109249","DOI":"10.1016\/j.biopha.2019.109249","volume":"118","author":"Y Lin","year":"2019","unstructured":"Lin Y, Jiang M, Chen W, Zhao T, Wei Y. Cancer and ER stress: mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomed Pharmacother. 2019;118:109249.","journal-title":"Biomed Pharmacother"},{"key":"3589_CR35","doi-asserted-by":"publisher","first-page":"216307","DOI":"10.1016\/j.canlet.2023.216307","volume":"570","author":"Y Qin","year":"2023","unstructured":"Qin Y, Ashrafizadeh M, Mongiardini V, Grimaldi B, Crea F, Rietdorf K, et al. Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence. Cancer Lett. 2023;570:216307.","journal-title":"Cancer Lett"},{"key":"3589_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10555-018-9727-z","volume":"37","author":"CK Das","year":"2018","unstructured":"Das CK, Mandal M, K\u00f6gel D. Pro-survival autophagy and cancer cell resistance to therapy. Cancer Metastasis Rev. 2018;37:749\u201366.","journal-title":"Cancer Metastasis Rev"},{"key":"3589_CR37","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/cancers11111775","volume":"11","author":"CJ Ho","year":"2019","unstructured":"Ho CJ, Gorski SM. Molecular mechanisms underlying Autophagy-Mediated treatment resistance in cancer. Cancers. 2019;11:1775.","journal-title":"Cancers"},{"key":"3589_CR38","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1038\/cddis.2013.350","volume":"4","author":"X Sui","year":"2013","unstructured":"Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4:e838\u2013838.","journal-title":"Cell Death Dis"},{"key":"3589_CR39","doi-asserted-by":"publisher","first-page":"102309","DOI":"10.1016\/j.nano.2020.102309","volume":"31","author":"EM Miller","year":"2021","unstructured":"Miller EM, Samec TM, Alexander-Bryant AA. Nanoparticle delivery systems to combat drug resistance in ovarian cancer. Nanomed Nanotechnol Biol Med. 2021;31:102309.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"3589_CR40","doi-asserted-by":"publisher","unstructured":"Wang X, Xiong T, Cui M, Li N, Li Q, Zhu L, et al. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway. J Nanobiotechnol. 2021;19. https:\/\/doi.org\/10.1186\/s12951-021-01139-1.","DOI":"10.1186\/s12951-021-01139-1"},{"key":"3589_CR41","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.3390\/cancers13215480","volume":"13","author":"M McFadden","year":"2021","unstructured":"McFadden M, Singh SK, Oprea-Ilies G, Singh R. Nano-Based drug delivery and targeting to overcome drug resistance of ovarian cancers. Cancers. 2021;13:5480.","journal-title":"Cancers"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03589-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03589-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03589-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:36:20Z","timestamp":1781649380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03589-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3589"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03589-z","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of Hengyang Medical School, University of South China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}